Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
SEC Accession No. 0001415889-25-024104
Filing Date
2025-09-10
Accepted
2025-09-10 16:59:33
Documents
1
Period of Report
2025-08-18

Document Format Files

Seq Description Document Type Size
1 form4a-09102025_080929.html 4/A  
1 form4a-09102025_080929.xml 4/A 3865
  Complete submission text file 0001415889-25-024104.txt   5333
Mailing Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010 (212) 547-9879
Lexeo Therapeutics, Inc. (Issuer) CIK: 0001907108 (see all company filings)

EIN.: 854012572 | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O LEXEO THERAPEUTICS, INC. 345 PARK AVENUE SOUTH, 6TH FLOOR NEW YORK NY 10010
Business Address
Townsend Richard Nolan (Reporting) CIK: 0001995218 (see all company filings)

Type: 4/A | Act: 34 | File No.: 001-41855 | Film No.: 251306468